SLV 313

Drug Profile

SLV 313

Alternative Names: SLV-313

Latest Information Update: 08 Mar 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Solvay
  • Class Antipsychotics; Piperazines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bipolar disorders; Schizophrenia

Most Recent Events

  • 19 Nov 2008 Preclinical pharmacodynamics data presented at the 38th Annual Meeting of the Society for Neuroscience (SfN-2008) ,
  • 04 Mar 2008 SLV 313 is still in Phase I trials for Schizophrenia in USA
  • 05 Mar 2007 Phase-I clinical trials in Bipolar disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top